BIBF 1120 for the treatment of non-small cell lung cancer

Expert Opinion on Investigational Drugs

Volumn 19, Issue 6, 2010, Pages 789-794

  Reck, Martin ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

Angiogenesis; BIBF 1120; NSCLC; Tyrosine kinase inhibitors; VEGFR

Indexed keywords

BIBF 1120; CARBOPLATIN; DOCETAXEL; FIBROBLAST GROWTH FACTOR RECEPTOR; PACLITAXEL; PEMETREXED; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIARRHEA; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; GLIOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; OVARY CARCINOMA; PROGRESSION FREE SURVIVAL; PROSTATE CARCINOMA; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; TUMOR REGRESSION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEMS; HUMANS; INDOLES; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77952345253     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.488220     Document Type: Review

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-249
2. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83(5):584-594
3. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18(10):2095-2103
4. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22(9):1589-1597
5. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372(9652):1809-1818
6. Quesada AR, Medina MA, Alba E. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Bioessays 2007;29(11):1159-1168
7. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362(6423):841-844
8. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(6 Suppl 16):15-18
9. Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor (VEGF) inhibition-a critical review. Anticancer Agents Med Chem 2007;7(2):223-245
10. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9(Suppl 1):2-10
11. Shojaei F, Ferrara N. Antiangiogenic therapy for cancer: an update. Cancer J 2007;13(6):345-348
12. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131(6):1190- 1203
13. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10(2):116-129
14. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309
15. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-2550
16. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009;27(8):1227-1234
17. Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009;101(9):1543-1548
18. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(11):1835-1842
19. Hilberg F, Roth GJ, Krssak M, et al. BIBF1120: Triple angiokinase inhibitor with sustained receptor blockade and good anti-tumor efficacy. Cancer Res 2008;68(12):4774-4782
20. Hilberg F, Brandstetter I, Roth GJ. In vitro and in vivo efficacy of BIBF 1120, a small molecule triple angiokinase inhibitor, in combination with taxanes. Proceedings AACR-NCI-EORTC. Int Conf Mol Targets Cancer Ther 2005;59:A19
21. Stopfer P, Roth W, Mross KB, et al. Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients. Eur J Cancer Suppl 2006;4(12):26
22. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16(1):311-319
23. Lee CP, Taylor NJ, Attard G, et al. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). J Clin Oncol 2006;24(18S):3015
24. Kaneda H, Okamoto I, Satoh T, et al. Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumours (and presentation). Eur J Cancer Suppl 2009;7(2):abstract 1243
25. Camidge DR, Conkling P, Stephenson J, Shapiro D. A phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). J Thoracic Oncol 2007;2(8):S730
26. Hanna N, Ellis P, Stopfer P, et al. A phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer. J Thoracic Oncol 2007;2(8):S717
27. von Pawel J, Kaiser R, Eschbach C, et al. Efficacy, safety and pharmacokinetic (PK) results of a Phase II study with the triple angiokinase inhibitor BIBF 1120 in patients suffering from advanced non small cell lung cancer (NSCLC). J Thoracic Oncol 2008;3(4):S61
28. LUME-Lung 1: BIBF 1120 plus docetaxel as compared to placebo plus docetaxel in 2nd line NSCLC. ClinicalTrialsgov 2008; LUME-Lung 1 study. Available from: http://clinicaltrials.gov/ct2/show/NCT00805194?term= BIBF+1120&rank=6. [Cited 15 April 2009]
29. LUME-Lung 2: BIBF 1120 plus pemetrexed compared to placebo plus pemetrexed in 2nd line nonsquamous NSCLC. ClinicalTrialsgov 2008; LUME-Lung 2 study. Available from: http://clinicaltrials.gov/ct2/show/NCT00806819?term=BIBF +1120&rank=4. [Cited 15 April 2009]
30. Roth GJ, Heckel A, Colbatzky F, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem 2009;52(14):4466-4480